SMAD1 and neoplasm: To target the tumor suppressive SMAD1/S1PR2 pathway and the leukemia-supporting IRE1/XBP1s pathway, we used the S1PR2 agonist CYM-5520 and the IRE1 inhibitor B-I09, respectively.